- Home
- WIW vs TLRY Comparison
WIW vs TLRY Comparison
Compare WIW & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIW
- TLRY
- Stock Information
- Founded
- WIW 2004
- TLRY N/A
- Country
- WIW United States
- TLRY Canada
- Employees
- WIW N/A
- TLRY N/A
- Industry
- WIW Finance Companies
- TLRY Medicinal Chemicals and Botanical Products
- Sector
- WIW Finance
- TLRY Health Care
- Exchange
- WIW Nasdaq
- TLRY Nasdaq
- Market Cap
- WIW 537.8M
- TLRY 637.2M
- IPO Year
- WIW N/A
- TLRY 2018
- Fundamental
- Price
- WIW $8.52
- TLRY $0.45
- Analyst Decision
- WIW
- TLRY Hold
- Analyst Count
- WIW 0
- TLRY 4
- Target Price
- WIW N/A
- TLRY $1.58
- AVG Volume (30 Days)
- WIW 229.9K
- TLRY 26.1M
- Earning Date
- WIW 01-01-0001
- TLRY 04-08-2025
- Dividend Yield
- WIW 11.14%
- TLRY N/A
- EPS Growth
- WIW N/A
- TLRY N/A
- EPS
- WIW N/A
- TLRY N/A
- Revenue
- WIW N/A
- TLRY $826,656,000.00
- Revenue This Year
- WIW N/A
- TLRY $11.80
- Revenue Next Year
- WIW N/A
- TLRY $5.41
- P/E Ratio
- WIW N/A
- TLRY N/A
- Revenue Growth
- WIW N/A
- TLRY 11.22
- 52 Week Low
- WIW $8.01
- TLRY $0.43
- 52 Week High
- WIW $9.37
- TLRY $2.52
- Technical
- Relative Strength Index (RSI)
- WIW 44.30
- TLRY 29.90
- Support Level
- WIW $8.45
- TLRY $0.46
- Resistance Level
- WIW $8.55
- TLRY $0.52
- Average True Range (ATR)
- WIW 0.11
- TLRY 0.05
- MACD
- WIW -0.01
- TLRY -0.01
- Stochastic Oscillator
- WIW 34.55
- TLRY 8.33
About WIW Western Asset Inflation-Linked Opportunities & Income Fund
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. Its primary investment objective of the group is to provide current income for its shareholders. The secondary investment objective is capital appreciation with current income.
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.